The company states: “Sanofi is disappointed with the Federal Trade Commission’s announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics. The agreement, announced on May 1, 2023, is for MZE001, a glycogen synthase 1 inhibitor program that has completed Phase 1 and is in development for Pompe Disease, a rare, inherited and often fatal disorder that disables the heart and skeletal muscles. We respectfully disagree with the action by the FTC which also delays potential advancements that could impact the lives of patients. The Maze partnership was designed to apply Sanofi’s resources, knowledge, and expertise to accelerate the development of MZE001, with the hope of addressing unmet medical needs for this devastating condition. The delay associated with a long litigation has led Sanofi to conclude that it would not be in the best interests of patients to contest this litigation and Sanofi will therefore be terminating the agreement with Maze in accordance with its terms. Sanofi remains committed to address the Pompe patient community’s unmet needs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNY:
- Sanofi says Sarclisa Phase 3 trial met primary endpoint
- Sanofi says 12 new molecular entities with ‘blockbuster potential’ in pipeline
- White House to back controversial patent ploy to fight drug costs, STAT says
- Sanofi just downgraded at JPMorgan, here’s why
- Weight-loss drug developers rise after Roche agrees to buy Carmot